Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Covidien's ablation system gets US nod for liver tumours

This article was originally published in Clinica

Executive Summary

The Evident microwave ablation system developed by Covidien has received US 510(k) clearance for use in the ablation of nonresectable liver tumours. The Evident technology can be used to coagulate soft tissue during percutaneous, laparoscopic and open surgical procedures in patients who cannot otherwise be treated surgically. As the system uses microwave ablation, there is no current flow through the patient, eliminating the need for grounding pads, the Boulder, Colorado firm said. Covidien claims that the Evident permits ablation procedures to be performed up to 60% faster than is possible with other ablation products, with ablations being achieved "in approximately 10 minutes".

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT043537

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel